Registration is open for the following webinar:
Pluripotent stem cells (PSC) are a promising source of in vitro-generated specialized cells for disease modeling, drug discovery, and cell therapy. However, large-scale cell differentiation is necessary to achieve this potential. Trailhead Biosystems utilizes the High-Dimensional Design of Experiments (HD-DoE™) platform to revolutionize the scientific discovery process in the field of developmental biology. This technology allows us to efficiently explore and optimize cell growth and differentiation processes. The company accelerates the development of precisely differentiated stem cells and cell therapy products. It’s a cornerstone of our approach to advancing regenerative medicine and personalized healthcare, enabling us to make significant breakthroughs in biotechnology. Trailhead Biosystems conducts experiments to control cell lineages effectively. The focus is on empirical data and unbiased determination of critical process parameters, building all our protocols from scratch.
In this webinar, you will learn about
- How Trailhead Biosystems has innovated large-scale cell differentiation with the HD-DoE™ platform
- How rigorous science and in-depth QC can result in superior cellular data and results
- How Trailhead Biosystems used iPSCs generated via REPROCELL's StemRNA Reprogramming Technology to develop their differentiation protocols of cells to support future clinical work.
About the Speaker
Dr. Jan Jensen, Ph.D. is the founder, CEO & CSO of Trailhead Biosystem. Dr. Jensen is an internationally renowned molecular developmental biologist and bioinformatician. He held the Eddie J. Brandon endowed professorship at Cleveland Clinic in Diabetes research. Jan is the founder of Trailhead Biosystems and has led numerous technology advances related to the control of many types of stem cells. He is cited among the top 1% globally for his scientific contributions.
In addition to his work on our HD-DOE platform and our analytical technologies applied to mapping cellular fate spaces, Jan’s discoveries include the identification of the fourth major autoantigen in diabetes, ZnT8; and the discovery of the mechanism of how insulin-producing cells develop in the organism. His broad interest in the fundamental principles in cellular differentiation has provided him a basis for his integrative approaches to complex living systems.
Jan covers multiple biological specialties through this work, such as precision medicine in cancer combinatorial drug development, anti-viral combinatorial drug development, stem cell differentiation of human cells, and methods development for regenerative medicine and cell-based therapy. Jan has leadership experience within multinational research collaboratives and more than 25 years of experience in research coordination.
In his approach to his work, Jan constantly challenges the limitations of the scientific process as it is currently applied, believing that system-level interrogations emerge as vastly superior to human-centered hypothesis-driven exploration.
https://www.linkedin.com/in/janjensen1/